{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:26Z","timestamp":1792623866432,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24AA022002"],"award-info":[{"award-number":["U24AA022002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T35 GRANT"],"award-info":[{"award-number":["T35 GRANT"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>When considering adherence to antiretroviral therapy (ART) for HIV, many different cut-points are used. The primary goals of this study were to identify a level of self-reported medication adherence that best distinguished HIV viral suppression from non-suppression, and to compare the ability of a single-item and a 3-item adherence questionnaire to predict HIV viral suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional analysis included 380 persons with HIV (PWH) from the Florida Cohort study who completed a self-reported ART adherence measure within 30-days of having an HIV viral load test. We used Receiver Operating Characteristic (ROC) curve analyses and ROCContrast to compare the ability of a single-item and a 3-item self-reported adherence measure to predict HIV viral suppression (defined as \u2264 200 copies\/mL). We used the Youden index and chi square statistics to assess specific cut-points, and repeated the analysis with a different definition of HIV viral suppression (\u2264 1000 copies\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean percent adherence was 92.4% using the single-item score and 90.4% using the 3-item score; 81.6% had viral suppression. The areas under the curve for the single-item and 3-item adherence measures were generally poor overall and not significantly different from each other (0.589 and 0.580, p = 0.67). The Youden index identified cut-points of 93% and 89% as maximizing the sensitivity and specificity for the single-item and 3-item measures, respectively, whereas a cut-point of 80% on the single-item measure was best able to discriminate those with viral suppression (58% vs. 84%, p &lt; 0.001). Results were similar with viral suppression defined as \u2264 1000 copies\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this sample of PWH, a single question on medication adherence was as good as a 3-item questionnaire in predicting HIV viral suppression, although neither had good discriminatory ability. A cut-point close to 90% adherence maximized sensitivity and specificity, although viral suppression was very similar for nearly all measures above 80%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-021-00358-8","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:02:56Z","timestamp":1624690976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Defining the optimal cut-point of self-reported ART adherence to achieve viral suppression in the era of contemporary HIV therapy: a cross-sectional study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-0874","authenticated-orcid":false,"given":"Emma","family":"O\u2019Halloran Leach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"issue":"9","key":"358_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/00002030-200106150-00015","volume":"15","author":"DR Bangsberg","year":"2001","unstructured":"Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181\u20133.","journal-title":"AIDS."},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.puhe.2016.05.004","volume":"139","author":"J Poorolajal","year":"2016","unstructured":"Poorolajal J, Hooshmand E, Mahjub H, Esmailnasab N, Jenabi E. Survival rate of AIDS disease and mortality in HIV-infected patients: a meta-analysis. Public Health. 2016;139:3\u201312.","journal-title":"Public Health"},{"issue":"1","key":"358_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/QAD.0b013e3282f366ff","volume":"22","author":"EM Gardner","year":"2008","unstructured":"Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008;22(1):75\u201382.","journal-title":"AIDS."},{"issue":"1","key":"358_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7326\/0003-4819-135-1-200107030-00005","volume":"135","author":"EL Murphy","year":"2001","unstructured":"Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17\u201326.","journal-title":"Ann Intern Med."},{"issue":"15","key":"358_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1001\/jama.2013.278328","volume":"310","author":"A Anglemyer","year":"2013","unstructured":"Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA. 2013;310(15):1619\u201320.","journal-title":"JAMA."},{"key":"358_CR6","unstructured":"Adolescents. DoHaHSPoAGfAa. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Department of Health and Human Services 2019. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"issue":"9","key":"358_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","volume":"21","author":"M May","year":"2007","unstructured":"May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thi\u00e9baut R, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185\u201397.","journal-title":"AIDS."},{"issue":"12","key":"358_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","volume":"126","author":"JW Mellors","year":"1997","unstructured":"Mellors JW, Mu\u00f1oz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946\u201354.","journal-title":"Ann Intern Med."},{"issue":"1","key":"358_CR9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/09540120600652303","volume":"19","author":"D Rao","year":"2007","unstructured":"Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007;19(1):28\u201333.","journal-title":"AIDS Care."},{"issue":"3","key":"358_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/108729100317948","volume":"14","author":"KJ Roberts","year":"2000","unstructured":"Roberts KJ. Barriers to and facilitators of HIV-positive patients\u2019 adherence to antiretroviral treatment regimens. AIDS Patient Care STDS. 2000;14(3):155\u201368.","journal-title":"AIDS Patient Care STDS."},{"issue":"1","key":"358_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11904-018-0377-0","volume":"15","author":"JR Castillo-Mancilla","year":"2018","unstructured":"Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV\/AIDS Rep. 2018;15(1):49\u201359.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"358_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"DL Paterson","year":"2000","unstructured":"Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21\u201330.","journal-title":"Ann Intern Med"},{"issue":"5","key":"358_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s12529-013-9353-7","volume":"21","author":"SC Kalichman","year":"2014","unstructured":"Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811\u201320.","journal-title":"Int J Behav Med"},{"issue":"5","key":"358_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"6","key":"358_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10865-016-9770-6","volume":"39","author":"DJ Finitsis","year":"2016","unstructured":"Finitsis DJ, Pellowski JA, Huedo-Medina TB, Fox MC, Kalichman SC. Visual analogue scale (VAS) measurement of antiretroviral adherence in people living with HIV (PLWH): a meta-analysis. J Behav Med. 2016;39(6):1043\u201355.","journal-title":"J Behav Med"},{"issue":"3","key":"358_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10461-006-9078-6","volume":"10","author":"JM Simoni","year":"2006","unstructured":"Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227\u201345.","journal-title":"AIDS Behav"},{"issue":"3","key":"358_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1345\/aph.1P587","volume":"45","author":"AB Kobin","year":"2011","unstructured":"Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372\u20139.","journal-title":"Ann Pharmacother"},{"key":"358_CR18","unstructured":"National Center for HIV\/AIDS VH, STD, and TB Prevention. Understanding the HIV Care Continuum. In: Prevention CfDCa, editor. 2019."},{"issue":"10","key":"358_CR19","doi-asserted-by":"publisher","first-page":"0240817","DOI":"10.1371\/journal.pone.0240817","volume":"15","author":"SN Rich","year":"2020","unstructured":"Rich SN, Cook RL, Yaghjyan L, Francois K, Puttkammer N, Robin E, et al. Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013\u20132017. PLoS ONE. 2020;15(10):0240817.","journal-title":"PLoS ONE"},{"key":"358_CR20","unstructured":"World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection : recommendations for a public health approach. Geneva: World Health Organization,; 2016. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK374294\/."},{"key":"358_CR21","doi-asserted-by":"crossref","unstructured":"Iba\u00f1ez GE, Zhou Z, Cook CL, Slade TA, Somboonwit C, Morano J, et al. The Florida Cohort study: methodology, initial findings and lessons learned from a multisite cohort of people living with HIV in Florida. AIDS Care. 2020:1-9.","DOI":"10.1080\/09540121.2020.1748867"},{"issue":"11","key":"358_CR22","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s10461-016-1406-x","volume":"20","author":"IB Wilson","year":"2016","unstructured":"Wilson IB, Lee Y, Michaud J, Fowler FJ, Rogers WH. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700\u20138.","journal-title":"AIDS Behav"},{"issue":"1","key":"358_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/01.ede.0000147512.81966.ba","volume":"16","author":"EF Schisterman","year":"2005","unstructured":"Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16(1):73\u201381.","journal-title":"Epidemiology."},{"key":"358_CR24","unstructured":"Rohilla Shalizi C. Advanced Data Analysis from an Elementary Point of View 2013 http:\/\/www.stat.cmu.edu\/~cshalizi\/ADAfaEPoV\/."},{"issue":"2","key":"358_CR25","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/jpepsy\/jst062","volume":"39","author":"EA Youngstrom","year":"2014","unstructured":"Youngstrom EA. A primer on receiver operating characteristic analysis and diagnostic efficiency statistics for pediatric psychology: we are ready to ROC. J Pediatr Psychol. 2014;39(2):204\u201321.","journal-title":"J Pediatr Psychol"},{"key":"358_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1186\/1471-2458-14-1035","volume":"14","author":"RZ Sangeda","year":"2014","unstructured":"Sangeda RZ, Mosha F, Prosperi M, Aboud S, Vercauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health. 2014;14:1035.","journal-title":"BMC Public Health"},{"issue":"3","key":"358_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/09540120050042891","volume":"12","author":"MA Chesney","year":"2000","unstructured":"Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255\u201366.","journal-title":"AIDS Care"},{"issue":"4","key":"358_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/QAI.0b013e318158a44f","volume":"46","author":"NR Reynolds","year":"2007","unstructured":"Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, Chesney MA. Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402\u20139.","journal-title":"J Acquir Immune Defic Syndr."},{"key":"358_CR29","doi-asserted-by":"crossref","unstructured":"Hinkin C, Hardy D, Mason K, Castellon S, Durvasula R, Lam M, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS2004.","DOI":"10.1097\/00002030-200418001-00004"},{"key":"358_CR30","unstructured":"Adolescents. PoAGfAa. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services."},{"issue":"4","key":"358_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s13181-015-0494-8","volume":"11","author":"PR Chai","year":"2015","unstructured":"Chai PR, Castillo-Mancilla J, Buffkin E, Darling C, Rosen RK, Horvath KJ, et al. Utilizing an ingestible biosensor to assess real-time medication adherence. J Med Toxicol. 2015;11(4):439\u201344.","journal-title":"J Med Toxicol"},{"issue":"27","key":"358_CR32","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"358_CR33","first-page":"53","volume":"8","author":"AK Kumar","year":"2006","unstructured":"Kumar AK, Ramachandran G, Kumar P, Kumaraswami V, Swaminathan S. Can urine lamivudine be used to monitor antiretroviral treatment adherence? MedGenMed. 2006;8(4):53.","journal-title":"MedGenMed"},{"issue":"4","key":"358_CR34","doi-asserted-by":"publisher","first-page":"e0154421","DOI":"10.1371\/journal.pone.0154421","volume":"11","author":"J Yan","year":"2016","unstructured":"Yan J, Liu J, Su B, Pan X, Wang Z, Wu J, et al. Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China. PLoS ONE. 2016;11(4):e0154421.","journal-title":"PLoS ONE"},{"issue":"10","key":"358_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/cid\/cit529","volume":"57","author":"C Laprise","year":"2013","unstructured":"Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489\u201396.","journal-title":"Clin Infect Dis"},{"key":"358_CR36","unstructured":"Ribaudo H Lennox J CJ. Virological failure endpoint definition in clinical trials: Is using HIV-1RNA threshold <200 copies\/mL better than 50 copies\/mL? An analysis of the ACTG studies.: Paper presented at: Conference on Retroviruses and Opportunistic Infections; Montreal, Canada.; 2009."},{"issue":"4","key":"358_CR37","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","volume":"19","author":"S Viswanathan","year":"2015","unstructured":"Viswanathan S, Detels R, Mehta SH, Macatangay BJ, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601\u201311.","journal-title":"AIDS Behav."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00358-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-021-00358-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-021-00358-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:05:51Z","timestamp":1624691151000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-021-00358-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s12981-021-00358-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent. The research procedures were approved by IRBs at the University of Florida, Florida International University, and the Florida Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}